Last reviewed · How we verify
NCT07209852: SEPTA PMCF
Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area - Post-Market Clinical Follow-up
trial testing Pacemaker lead in Bradycardia in 140 participants. Currently enrolling.
31 August 2029
Quick facts
| Lead sponsor | Boston Scientific Corporation |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 140 |
| Start date | 19 December 2025 |
| Primary completion | 31 August 2029 |
| Estimated completion | 31 August 2029 |
| Sites | 13 locations across France, Italy, Belgium, United Kingdom, Germany, Switzerland, Spain |
Drugs / interventions tested
- Pacemaker lead
Conditions studied
- Bradycardia — all drugs for Bradycardia →
- Atrioventricular Block — all drugs for Atrioventricular Block →
- Sinus Node Dysfunction — all drugs for Sinus Node Dysfunction →
- Bundle-Branch Block — all drugs for Bundle-Branch Block →
Sponsor
Boston Scientific Corporation — full company profile →
Who can join
18 and older, any sex, with Bradycardia or Atrioventricular Block. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational post-market clinical Follow-up study is to learn about the long-term safety, performance, and clinical benefits of pacing the left bundle branch area (LBBAP) using the INGEVITY+ pacemaker lead in patients with bradycardia who need a pacemaker.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07209852
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bradycardia
Currently open trials in the same condition.
- NCT07254013 — Left Bundle Branch Area Pacing (LBBAP) Monitoring Assistant: Evaluation of Portable ECG Solution · NA · recruiting
- NCT07166614 — Dexmedetomidine vs Propofol in High-Risk ERCP Patients · NA · recruiting
- NCT07585799 — Permanent Conduction System Pacing Versus Atrioventricular Management for Patients With Wide QRS and Patent AV Conductio · NA · recruiting
- NCT07217392 — Left Bundle Branch Area Pacing (LBBAP) PMCF Study · NA · recruiting
- NCT07018648 — Clinical Safety and Efficacy Testing of a Medical Device Kardi Ai, an ECG Telemetry Monitoring System · NA · recruiting
Other Boston Scientific Corporation trials
Trials by the same sponsor.
- NCT07458243 — Registry of ENROUTE NPS in Conjunction With Carotid WALLSTENT · not yet recruiting
- NCT07458217 — Combined CM and STN Stimulation for Motor Epilepsy · NA · not yet recruiting
- NCT07276815 — OverStitch NXT Endoscopic Suture System · NA · not yet recruiting
- NCT07353710 — A Study on the Acquisition of 2D ICE Images With the CHORUS IDx System in Subjects Undergoing an Ablation Procedure · NA · not yet recruiting
- NCT07195708 — Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365') · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07209852 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boston Scientific Corporation
- Last refreshed: 3 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07209852.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing